Empowering Mesenchymal Stem Cells for Ocular Degenerative Disorders

Int J Mol Sci. 2019 Apr 10;20(7):1784. doi: 10.3390/ijms20071784.

Abstract

Multipotent mesenchymal stem cells (MSCs) have been employed in numerous pre-clinical and clinical settings for various diseases. MSCs have been used in treating degenerative disorders pertaining to the eye, for example, age-related macular degeneration, glaucoma, retinitis pigmentosa, diabetic retinopathy, and optic neuritis. Despite the known therapeutic role and mechanisms of MSCs, low cell precision towards the targeted area and cell survivability at tissue needing repair often resulted in a disparity in therapeutic outcomes. In this review, we will discuss the current and feasible strategy options to enhance treatment outcomes with MSC therapy. We will review the application of various types of biomaterials and advances in nanotechnology, which have been employed on MSCs to augment cellular function and differentiation for improving treatment of visual functions. In addition, several modes of gene delivery into MSCs and the types of associated therapeutic genes that are important for modulation of ocular tissue function and repair will be highlighted.

Keywords: degeneration; mesenchymal stem cells; ocular disorders.

Publication types

  • Review

MeSH terms

  • Diabetic Retinopathy* / metabolism
  • Diabetic Retinopathy* / pathology
  • Diabetic Retinopathy* / therapy
  • Glaucoma* / metabolism
  • Glaucoma* / pathology
  • Glaucoma* / therapy
  • Humans
  • Mesenchymal Stem Cell Transplantation*
  • Mesenchymal Stem Cells / metabolism*
  • Mesenchymal Stem Cells / pathology
  • Optic Neuritis* / metabolism
  • Optic Neuritis* / pathology
  • Optic Neuritis* / therapy
  • Retinitis Pigmentosa* / metabolism
  • Retinitis Pigmentosa* / pathology
  • Retinitis Pigmentosa* / therapy